Competition Law and Biological Computing Market Concentration

1. Introduction

Biological computing refers to computing systems and platforms that use biological information, biological processes, or biological data as a core computational resource. It can include DNA-based computation, genomic data processing, bioinformatics platforms, computational biology, synthetic biology software, biological AI, genomic databases, sequencing analytics, and cloud-based biological-data platforms.

Market concentration in this sector can arise because biological computing markets often have:

• very high research and development costs;
• substantial intellectual-property portfolios;
• proprietary datasets;
• network effects;
• interoperability and technical-standard advantages;
• high switching costs for researchers and laboratories;
• economies of scale in sequencing and computation;
• access to clinical/genomic datasets;
• vertically integrated sequencing, software and diagnostic ecosystems; and
• strong first-mover advantages.

Competition law therefore has to examine not merely current market share, but also control over data, infrastructure, algorithms, interoperability, intellectual property and future innovation.

The most directly relevant modern competition disputes are the Illumina–PacBio and Illumina–GRAIL matters, because they demonstrate how concentration in genetic-sequencing infrastructure can affect downstream biological-computing and diagnostic innovation.

2. Meaning of Market Concentration in Biological Computing

Market concentration exists when a relatively small number of undertakings control a substantial portion of a relevant market.

In biological computing, concentration may exist at several different levels:

A. Hardware concentration

A small number of companies may control:

• DNA sequencing machines;
• high-throughput sequencing systems;
• biological sensors;
• laboratory automation;
• specialized biological-computing hardware.

B. Software concentration

Concentration may occur in:

• genomic-analysis software;
• bioinformatics platforms;
• laboratory-information systems;
• computational biology platforms;
• AI-driven genomic interpretation;
• cloud-based biological computation.

C. Data concentration

A firm may possess uniquely valuable:

• genomic datasets;
• clinical datasets;
• phenotype datasets;
• longitudinal patient data;
• biological research datasets.

D. Infrastructure concentration

A platform may control:

• sequencing infrastructure;
• cloud infrastructure;
• APIs;
• computational pipelines;
• data repositories;
• research interfaces.

E. Vertical concentration

A company may simultaneously operate:

sequencing hardware → biological data → analytical software → diagnostic application → downstream healthcare product.

This vertical structure is particularly important because the firm can potentially disadvantage competitors operating at downstream levels.

3. Relevant Market Definition

Competition authorities should avoid defining the market simply as the entire "biological computing industry."

Possible relevant markets include:

Product markets

1. DNA-sequencing systems;
2. long-read sequencing;
3. short-read sequencing;
4. genomic data-analysis software;
5. clinical genomic interpretation;
6. biological AI platforms;
7. genomic databases;
8. bioinformatics cloud services;
9. DNA-based computational systems;
10. specialized biological-computing infrastructure.

The Illumina/PacBio proceedings demonstrate why technological differentiation matters. The FTC characterized PacBio as a nascent competitive threat in next-generation DNA sequencing, while the proposed acquisition was abandoned before the proceeding was completed.

4. Geographic Market

The geographic market may be:

• national;
• regional;
• global; or
• segmented according to regulatory requirements.

For biological computing, a global market may be plausible where:

• software is distributed digitally;
• sequencing equipment is internationally traded;
• cloud computation is remotely accessible;
• scientific datasets are internationally usable.

However, healthcare regulation, privacy laws, medical-device approvals and data-localisation requirements can create narrower geographic markets.

5. Why Biological Computing Markets Can Become Highly Concentrated

A. Economies of scale

Sequencing and biological computation can involve enormous fixed costs.

A large incumbent can spread:

• R&D costs;
• computing costs;
• laboratory infrastructure costs;
• software-development costs; and
• data-acquisition costs

over a much larger customer base.

B. Data advantages

A biological-computing platform with a large dataset can potentially improve:

• prediction;
• genomic interpretation;
• disease classification;
• biomarker discovery;
• algorithmic accuracy.

This can create a feedback loop:

more users → more data → better algorithms → more users → still more data.

Such a mechanism may produce substantial entry barriers even where the underlying software itself is technically replicable.

C. Network effects

Researchers may prefer platforms where:

• more laboratories participate;
• more datasets are available;
• more analytical tools are compatible;
• more third-party developers contribute.

Consequently, a platform can become difficult to challenge after achieving sufficient scale.

D. Switching costs

Researchers may face significant costs in moving from one biological-computing ecosystem to another because of:

• incompatible data formats;
• proprietary APIs;
• retraining;
• migration expenses;
• validation requirements;
• regulatory validation;
• loss of historical datasets.

6. Vertical Integration

Vertical integration is one of the most important competition concerns.

Consider:

Sequencing company
↓
Genomic-data platform
↓
Bioinformatics software
↓
AI interpretation
↓
Diagnostic test

If one undertaking controls several levels, it may possess the ability and incentive to:

• raise rivals' costs;
• restrict access;
• discriminate against competing software;
• delay interoperability;
• provide preferential technical support;
• bundle products;
• use downstream information to compete against customers.

The Illumina/GRAIL litigation is an important example. The FTC alleged that Illumina controlled a critical sequencing input necessary for competing multi-cancer early-detection developers and could therefore potentially disadvantage downstream rivals.

7. Nascent Competition

Biological computing is particularly susceptible to nascent-competitor acquisition.

A start-up may currently possess:

• low revenue;
• little market share;
• few customers.

Nevertheless, it may possess technology capable of becoming a significant future competitor.

Competition authorities therefore examine:

1. technological capability;
2. R&D pipeline;
3. customer adoption;
4. patents;
5. scientific publications;
6. investment;
7. clinical validation;
8. probability of commercialisation.

The Illumina/PacBio case is particularly relevant because the FTC alleged that PacBio represented a nascent competitive threat to Illumina's position in next-generation sequencing.

8. Innovation Competition

Traditional concentration analysis focuses heavily on:

price + output + market share.

Biological computing requires greater attention to:

innovation + research + technological alternatives + future competition.

A merger may be problematic even where:

• prices do not immediately increase;
• customers have existing alternatives;
• the target has limited current revenue.

The concern may instead be that the transaction eliminates an independent source of future innovation.

The FTC's GRAIL proceeding specifically concerned the potential effect of the transaction on innovation in multi-cancer early-detection testing.

9. Data as a Competitive Asset

Biological data may constitute a critical competitive input.

Examples include:

• whole-genome sequences;
• clinical records;
• phenotype information;
• genomic variants;
• disease progression data;
• laboratory results;
• population datasets.

A dominant undertaking may obtain competitive advantages from exclusive access to such data.

Competition authorities may therefore investigate:

Data foreclosure

Whether competitors cannot obtain sufficiently comparable datasets.

Data portability

Whether customers can transfer their data to competing platforms.

Data interoperability

Whether competing systems can technically process or exchange information.

Data combination

Whether a merger allows two previously separate datasets to be combined in a way that materially strengthens market power.

10. Interoperability

Interoperability is particularly important in biological computing.

A dominant platform could potentially restrict:

• API access;
• file formats;
• sequencing-data interfaces;
• cloud integration;
• laboratory-system connectivity;
• third-party analytical tools.

A refusal to interoperate can become a competition issue when interoperability is indispensable for effective competition.

The classical EU cases concerning access to technical information, data and interoperability therefore provide useful analytical principles even where the underlying technology was not biological computing.

11. Intellectual Property and Market Concentration

Patents can create legitimate incentives to innovate.

However, competition concerns can arise where a dominant undertaking combines:

patent control + essential infrastructure + proprietary data + software + distribution.

Potential issues include:

• exclusionary licensing;
• discriminatory licensing;
• patent pools;
• tying;
• refusal to license;
• excessive licensing restrictions;
• patent-related acquisitions;
• strategic accumulation of complementary technologies.

Competition law does not generally treat ownership of intellectual property as unlawful merely because it creates market power.

The critical question is whether the exercise or combination of those rights produces conduct that harms competition beyond legitimate protection of innovation.

12. Six Important Case Laws

1. FTC v. Illumina, Inc. / Pacific Biosciences

Jurisdiction: United States
Authority: Federal Trade Commission
Year: 2019–2020

Facts

Illumina proposed acquiring Pacific Biosciences for approximately $1.2 billion.

The FTC challenged the transaction, alleging that Illumina was seeking to maintain its position in next-generation DNA sequencing by eliminating PacBio as a developing competitive threat.

The FTC alleged that the transaction could eliminate both existing and future competition.

The parties abandoned the transaction in January 2020.

Legal significance

The case demonstrates that:

• current market share is not the only relevant consideration;
• nascent competition can matter;
• differentiated sequencing technologies may nevertheless constrain each other;
• acquisition of a technological challenger can raise concentration concerns.

Application to biological computing

A dominant biological-computing platform acquiring an emerging:

• DNA-computing company;
• genomic-AI company;
• sequencing-analytics provider; or
• computational-biology platform

may receive similar scrutiny.

2. FTC v. Illumina, Inc. / GRAIL, Inc.

Jurisdiction: United States
Authority: FTC
Period: 2021–2024

This is one of the most important cases for biological-computing market concentration.

Illumina proposed acquiring GRAIL, which developed a multi-cancer early-detection test relying on DNA sequencing.

The FTC alleged that Illumina was the only viable U.S. supplier of sequencing technology for these tests and that the acquisition could allow Illumina to disadvantage competing developers.

The FTC Administrative Law Judge initially dismissed the challenge in 2022.

The Commission subsequently reversed that decision in 2023 and ordered divestiture.

The Fifth Circuit later found substantial evidence supporting the Commission's determination concerning competitive harm, while remanding on an issue concerning the treatment of rebuttal evidence. Illumina subsequently announced that it would divest GRAIL.

Legal significance

The case illustrates:

• vertical merger concerns;
• input foreclosure;
• access to critical sequencing technology;
• innovation competition;
• nascent downstream markets;
• control over biological infrastructure.

3. Illumina, Inc. and GRAIL LLC — Court of Justice of the European Union

Jurisdiction: European Union
Court: Court of Justice
Case: C-611/22 P
Judgment: 3 September 2024

The European Commission had accepted referrals concerning the Illumina/GRAIL transaction under Article 22 of the EU Merger Regulation.

The CJEU addressed whether the Commission could examine the transaction following referral requests from national competition authorities that themselves lacked jurisdiction under their national merger-control thresholds.

The Court annulled the Commission's decisions accepting the referrals.

Legal significance

For biological computing, the case demonstrates that:

• jurisdictional thresholds can become strategically important;
• transactions involving innovative biotechnology companies may escape traditional turnover-based screening;
• competition authorities may attempt to examine acquisitions involving low-revenue but strategically important innovators;
• legal certainty and jurisdiction remain important constraints.

The case is particularly significant for below-threshold acquisitions of biotechnology and biological-AI start-ups.

4. IMS Health v NDC Health

Court: Court of Justice of the European Union
Case: C-418/01
Year: 2004

Facts

IMS Health possessed a substantial position concerning pharmaceutical prescription-data structures used by pharmaceutical companies.

The case concerned access to a standardized data structure and whether refusal to supply could constitute an abuse of dominance in exceptional circumstances.

Legal significance

The Court developed important principles concerning refusal to supply/license intellectual-property-related assets.

The case is relevant where a biological-computing company controls a uniquely valuable:

• genomic database;
• biological-data architecture;
• data standard;
• analytical interface.

Application

A dominant genomic-data platform cannot automatically be required to share its database simply because competitors would benefit from access.

Exceptional circumstances and the established legal conditions for compulsory access remain important.

5. Microsoft Corp. v Commission

Court: General Court of the European Union
Case: T-201/04
Year: 2007

Facts

Microsoft was found to have abused its dominant position through, among other matters, its refusal to provide interoperability information to competing work-group server operating systems.

Legal significance

The case is important for biological computing because interoperability may become a competitive bottleneck.

For example, a dominant genomic platform could potentially control:

• sequencing-data interfaces;
• proprietary APIs;
• data-transfer protocols;
• laboratory software integration.

If competitors cannot effectively interoperate with the dominant ecosystem, competition may be weakened.

Application

The Microsoft principles provide a framework for analysing whether interoperability restrictions constitute exclusionary conduct.

6. Bronner v Mediaprint

Court: Court of Justice of the European Union
Case: C-7/97
Year: 1998

Principle

The case concerned the circumstances in which refusal to provide access to an infrastructure controlled by a dominant undertaking can amount to abuse.

The Court applied a demanding test for treating infrastructure as effectively indispensable.

Application to biological computing

Suppose one undertaking controls an infrastructure such as:

• a unique biological database;
• a sequencing platform;
• specialized biological-computing infrastructure;
• an indispensable computational interface.

A competitor's claim to access would need to satisfy stringent legal requirements.

Significance

Bronner prevents competition law from automatically converting every commercially valuable asset into a mandatory-access facility.

13. Additional Relevant Case: Magill

Cases: Joined Cases C-241/91 P and C-242/91 P
Court: CJEU

The Magill litigation concerned refusal to license copyrighted television listings.

The Court identified exceptional circumstances under which refusal to license intellectual property could constitute abuse.

Biological-computing relevance

The principles can become relevant to:

• proprietary biological databases;
• genomic annotation systems;
• biological-data standards;
• copyrighted bioinformatics resources.

The key lesson is that IP ownership and competition law must be balanced rather than treated as inherently conflicting.

14. Concentration Through Mergers

Biological-computing mergers can be divided into four principal categories.

15. Horizontal Concentration

Example:

Genomic-AI Platform A + Genomic-AI Platform B

Potential concerns include:

• loss of independent innovation;
• increased data concentration;
• reduced software alternatives;
• increased switching costs;
• reduced R&D rivalry.

The Illumina/PacBio proceedings illustrate the importance of considering future competition rather than merely existing customer overlap.

16. Vertical Concentration

Example:

Sequencing hardware company + genomic-analysis platform

The combined firm might theoretically:

• raise sequencing prices to rival software providers;
• delay access to new sequencing technology;
• restrict API access;
• bundle sequencing with proprietary software;
• obtain commercially sensitive information concerning downstream rivals.

The Illumina/GRAIL litigation provides the clearest modern illustration of this type of concern.

17. Conglomerate Concentration

A biological-computing company might operate across:

genomic database + AI model + cloud infrastructure + diagnostic software.

The firm could potentially use strength in one market to expand into another through:

• tying;
• bundling;
• preferential access;
• discounts;
• interoperability restrictions;
• exclusive contracts.

Competition authorities would normally need to establish the relevant markets and demonstrate the mechanism through which competition could be harmed.

18. Data Monopolisation

One of the distinctive issues in biological computing is data-based market power.

A company may not possess the largest software market share but may control a dataset that competitors cannot reproduce.

This can create:

Data → algorithmic advantage → customers → more data → stronger market position

Competition analysis may therefore consider:

• uniqueness;
• replicability;
• portability;
• quality;
• freshness;
• volume;
• interoperability;
• lawful availability of alternative datasets.

19. Algorithmic Concentration

Biological computing increasingly involves AI.

A dominant firm may control:

• training datasets;
• foundation models;
• genomic interpretation algorithms;
• computing infrastructure;
• APIs;
• model evaluation tools.

Potential concerns include:

Self-preferencing

The platform may favor its own biological applications.

Discriminatory API access

Third-party developers may receive inferior access.

Tying

Access to biological data may be conditioned on using proprietary AI.

Exclusive contracts

Laboratories may be prevented from using competing platforms.

Data accumulation

A dominant platform may use customer-generated biological data to strengthen its own competing product.

20. Barriers to Entry

Important barriers include:

Financial barriers

Large capital expenditure for:

• sequencing;
• computing;
• laboratories;
• data storage.

Scientific barriers

Need for:

• specialist expertise;
• validation;
• scientific credibility;
• clinical evidence.

Regulatory barriers

Biological and healthcare applications may require extensive regulatory approval.

Data barriers

New entrants may lack sufficiently large datasets.

Intellectual-property barriers

Patents and proprietary technology may make replication difficult.

Switching barriers

Researchers may have built workflows around an incumbent platform.

21. HHI and Concentration Analysis

Competition authorities may use the Herfindahl-Hirschman Index (HHI) or similar concentration measures.

The basic formula is:

HHI=∑si2HHI=\sum s_i^2

where sis_i represents the market share of each undertaking.

However, HHI should not be used mechanically in biological computing.

A market with several firms may still exhibit substantial competitive risk where:

• one firm controls an indispensable dataset;
• one firm controls critical infrastructure;
• competitors are dependent upon its APIs;
• technological differentiation is significant;
• entry is extremely difficult.

The Illumina/PacBio proceedings illustrate this point particularly well; the FTC's complaint treated the sequencing technologies as differentiated while still alleging that the acquisition could eliminate important competition.

22. Innovation Effects

Authorities should examine whether concentration could reduce:

• sequencing accuracy;
• computing efficiency;
• algorithmic innovation;
• diagnostic development;
• research tools;
• data-analysis techniques;
• biological discovery.

The effect can be especially important where the market is rapidly evolving.

A company with modest current sales may nevertheless represent substantial innovation competition.

23. Effects on Researchers and Laboratories

Market concentration can affect:

• research institutions;
• universities;
• hospitals;
• pharmaceutical companies;
• biotechnology start-ups;
• independent laboratories.

Potential effects include:

• higher software subscription costs;
• higher sequencing costs;
• reduced interoperability;
• restrictions on data portability;
• fewer technological alternatives;
• reduced access to innovative tools.

24. Competition Remedies

Where concentration creates competition concerns, authorities may consider:

Structural remedies

• divestiture;
• sale of a business unit;
• licensing of technology;
• separation of competing assets.

Behavioural remedies

• non-discrimination obligations;
• interoperability;
• API access;
• data portability;
• firewall requirements;
• prohibition of tying;
• access commitments.

Data remedies

• portability;
• standardized formats;
• controlled access;
• independent data governance;
• non-exclusive licensing.

The Illumina/GRAIL proceeding demonstrates that divestiture can be considered where behavioural commitments are insufficient to address vertical foreclosure concerns.

25. Application to India

For India, the principal framework is the Competition Act, 2002, administered by the Competition Commission of India (CCI).

Biological-computing concentration may potentially engage:

Section 4

Abuse of dominant position, including conduct such as:

• unfair or discriminatory conditions;
• unfair pricing;
• limiting markets;
• denial of market access;
• tying;
• leveraging dominance into another market.

Sections 5 and 6

Combination regulation may become relevant to:

• acquisitions of bioinformatics companies;
• sequencing-platform mergers;
• biotechnology acquisitions;
• biological-AI acquisitions;
• data-intensive healthcare technology transactions.

Section 3

Potentially relevant where biological-computing firms engage in:

• cartel arrangements;
• information exchange;
• market allocation;
• exclusive arrangements;
• anti-competitive agreements.

The analytical challenge is determining whether a biological dataset, platform, sequencing technology or computational interface constitutes a relevant competitive input or whether sufficiently effective substitutes exist.

26. Key Competition-Law Issues

A biological-computing concentration should therefore be tested against the following questions:

1. What is the relevant product market?
2. Is sequencing hardware distinct from sequencing software?
3. Is biological data substitutable?
4. Does one firm control a critical dataset?
5. Are competing datasets realistically replicable?
6. Does the firm control essential computational infrastructure?
7. Are APIs interoperable?
8. Are customers locked into proprietary formats?
9. Does the transaction eliminate a nascent competitor?
10. Does the merger reduce innovation competition?
11. Can the merged firm foreclose downstream competitors?
12. Can it use customer data to compete against those customers?
13. Are there network effects?
14. Are switching costs significant?
15. Can new entrants realistically enter?
16. Would behavioural remedies adequately preserve competition?

27. Case-Law Principles at a Glance

28. Emerging Competition Risks

The next generation of biological computing may create concentration around biological foundation models.

A company controlling:

massive genomic datasets + AI models + specialised chips + cloud computing + sequencing + diagnostic applications

could occupy multiple layers simultaneously.

This could produce a particularly powerful ecosystem.

The principal competition question will therefore move from:

"How much market share does the company have?"

toward:

"Which competitive inputs does the company control, how difficult are they to replicate, and can that control be leveraged across adjacent biological markets?"

29. Conclusion

Competition law concerning biological-computing market concentration requires a dynamic analysis.

Traditional market-share analysis remains relevant, but it is insufficient by itself. The distinctive characteristics of biological computing—particularly genomic data, sequencing infrastructure, intellectual property, interoperability, AI models, network effects and high R&D barriers—can create market power that is not fully captured by conventional concentration measures.

The Illumina/PacBio and Illumina/GRAIL proceedings are particularly significant because they demonstrate how competition authorities can scrutinize acquisitions involving genetic-sequencing infrastructure, nascent technologies and downstream innovation.

The broader principles from IMS Health, Microsoft, Bronner and Magill provide additional tools for analysing access, interoperability, infrastructure and intellectual-property issues.